DMII (Drugs Made In America Acquisition II) YoY EBITDA Growth: -100.00% (As of Mar. 2026)


DMII Drugs Made In America Acquisition II Corp DMII
15 GF Score
Price $10.10
! 1 Warning Sign
View Full Analysis

What is Drugs Made In America Acquisition II YoY EBITDA Growth?

Drugs Made In America Acquisition II DMII 15 YoY EBITDA Growth is -100.00% as of Mar. 2026. GuruFocus rates DMII with a GF Score™ of 15/100. The stock has 1 warning sign investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Drugs Made In America Acquisition II's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was -100.00%.

Drugs Made In America Acquisition II's EBITDA per Share for the three months ended in Mar. 2026 was $-0.00.

Drugs Made In America Acquisition II YoY EBITDA Growth Related Terms

Drugs Made In America Acquisition II YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Drugs Made In America Acquisition II's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Drugs Made In America Acquisition II YoY EBITDA Growth Chart

Drugs Made In America Acquisition II Annual Data
Trend Dec24 Dec25
YoY EBITDA Growth
0.00 0.00

Drugs Made In America Acquisition II Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 -100.00
DMII
15GF Score
Drugs Made In America Acquisition II Corp DMII
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Drugs Made In America Acquisition II YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Drugs Made In America Acquisition II's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.047-0)/ | 0 |
=N/A %

Drugs Made In America Acquisition II's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-0.002--0.001)/ | -0.001 |
=-100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of -100.00% mean?
Drugs Made In America Acquisition II (DMII) has a YoY EBITDA Growth of -100.00% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Drugs Made In America Acquisition II and its competitors.
Is Drugs Made In America Acquisition II's YoY EBITDA Growth too high?
Drugs Made In America Acquisition II's current YoY EBITDA Growth is -100.00%. Overall, Drugs Made In America Acquisition II has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition II's YoY EBITDA Growth compare to BCSS and EVAC?
Drugs Made In America Acquisition II's YoY EBITDA Growth of -100.00% can be compared against companies in the Diversified Financial Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Diversified Financial Services company?
A good YoY EBITDA Growth depends on the Diversified Financial Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Drugs Made In America Acquisition II and its competitors. Drugs Made In America Acquisition II's current YoY EBITDA Growth is -100.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition II stock overvalued right now?
Drugs Made In America Acquisition II (DMII) has a current YoY EBITDA Growth of -100.00%. The current YoY EBITDA Growth is -100.00%. Drugs Made In America Acquisition II's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Drugs Made In America Acquisition II (DMII), the current YoY EBITDA Growth is -100.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Drugs Made In America Acquisition II Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10170
Drugs Made In America Acquisition II Corp is a blank check Company.
15GF Score

Get the complete analysis for DMII

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.10
Price